Quidel Corporation (QDEL)

Currency in USD
16.32
-1.18(-6.74%)
Closed·
12.70-3.62(-22.18%)
·
Unusual Post-Market activity
QDEL is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
16.1717.34
52 wk Range
9.9235.58
Key Statistics
Prev. Close
16.32
Open
17.17
Day's Range
16.17-17.34
52 wk Range
9.92-35.58
Volume
2.75M
Average Volume (3m)
1.68M
1-Year Change
-33.1148%
Book Value / Share
27.19
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
QDEL Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
21.33
Upside
+30.72%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year

Quidel Corporation News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

1 Buy
1 Hold
1 Sell
Ratings:
3 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 21.33
(+30.72% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Citi
Hold18.00+10.29%13.00Maintain08-07-2026
JPMorgan
Sell12.00-26.47%11.00Maintain01-07-2026
Jefferies
Hold12.50-23.41%-Maintain29-06-2026
UBS
Hold12.00-26.47%17.00Maintain07-05-2026
Jefferies
Hold12.50-23.41%35.00Downgrade07-05-2026

Quidel Corporation SWOT Analysis


Financial Resilience
QuidelOrtho demonstrates strong Q2 2024 performance, with analysts projecting net income growth despite recent revenue challenges
Strategic Cost-Cutting
Explore the $100 million cost rationalization plan aimed at improving medium-term margins and enhancing QuidelOrtho's financial health
Savanna's Potential
Learn about the anticipated 2025 U.S. launch of Savanna, a key product expected to drive future revenue and market expansion for QuidelOrtho
Analyst Optimism
Delve into analyst perspectives, with price targets ranging from $38 to $64 and an average consensus recommendation of 2.38 on InvestingPro's scale
Read full SWOT analysis

Quidel Corporation Earnings Call Summary for Q2/2026

  • QuidelOrtho posted Q2 adjusted EPS of $0.13, beating estimates of a $0.04 loss, with revenue of $630.9M slightly above forecasts.
  • Company slashed full-year revenue guidance to $2.52B-$2.60B and withdrew free cash flow guidance amid China headwinds and weaker respiratory outlook.
  • China revenue plunged 23% YoY due to policy changes; core businesses outside China grew 6%, with adjusted EBITDA margin expanding 310bps to 20%.
  • Net debt leverage stands at 4.3x EBITDA with $2.87B total debt; stock plummeted 21% in after-hours trading despite initial gains.
  • Management projects Q3 EPS of $0.85 and Q4 EPS of $1.08, citing conservative respiratory season assumptions and ongoing operational improvements.
Last Updated: 07-08-2026, 03:26 am
Read Full Transcript

Earnings

Latest Release
30-07-2026
EPS / Forecast
0.13 / -0.04
Revenue / Forecast
630.9M / 619.53M
EPS Revisions
Last 90 days

QDEL Income Statement

Compare QDEL to Peers and Sector

Metrics to compare
QDEL
Peers
Sector
Relationship
P/E Ratio
−0.9x−2.8x−0.4x
PEG Ratio
0.00−0.100.00
Price/Book
0.6x2.2x2.6x
Price / LTM Sales
0.4x2.4x3.0x
Upside (Analyst Target)
−20.0%15.0%50.7%
Fair Value Upside
Unlock12.0%7.2%Unlock

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, to measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point of Care business unit provides instruments and tests to provide rapid results across a continuum of POC settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, Japan and Asia Pacific, and Latin America. The company was incorporated in 1979 and is headquartered in San Diego, California.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
45.34M66.49%793.25M
Other Institutional Investors
51.01M33.51%892.40M
Public Companies & Retail Investors
0.000.00%0.00
Total
96.35M100.00%1.69B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
BlackRock, Inc.15.32%1,04,49,1271,82,807
FMR LLC11.51%78,50,7591,37,349

FAQ

What Is the Quidel (QDEL) Share Price Today?

The Quidel share price today is 16.32.

What is the current Quidel (QDEL) share price and day range?

As of 07-08-2026, the Quidel share price is 16.32, with a previous close of 16.32. The share price has ranged from 16.17 to 17.34 today, while the 52-week range spans from 9.92 to 35.58.

What Is the Quidel Market Cap?

As of today, Quidel market cap is 1.11B.

What Is the Quidel (QDEL) Share Price Target?

The average 12-month share price target for Quidel is 21.33, with a high estimate of 38 and a low estimate of 12. 1 analysts recommend buying, while 1 suggest selling, with an overall rating of Neutral and +30.72% Upside potential.

What Is Quidel's Earnings Per Share (TTM)?

The Quidel EPS (TTM) is -17.81.

When Is the Next Quidel Earnings Date?

Quidel will release its next earnings report on 04-11-2026.

From a Technical Analysis Perspective, Is QDEL a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.

What Stock Exchange Does Quidel Trade On?

Quidel is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Quidel?

The stock symbol for Quidel is "QDEL."

How Many Times Has Quidel Stock Split?

Quidel has split 0 times.

How Many Employees Does Quidel Have?

Quidel has 6500 employees.

What Is the QDEL After Hours Price?

QDEL's last after hours stock price is 12.70, the stock has changed by -3.62, or -22.18%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.